Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
Comparative effectiveness of ten CPMs for acute exacerbation of chronic obstructive pulmonary disease: systematic
Keying Li1, Wenrui Huang1, Tuliang Liang2
1The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
Background:
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a prevalent acute respiratory disease in China, necessitating effective treatments.
Purpose:
To investigate the therapeutic and safety profiles of Chinese patent medicines (CPMs) for AECOPD.
Methods:
Randomized controlled trials (RCTs) investigating CPMs for AECOPD were retrieved from PubMed, Cochrane Library, Embase, Web of Science, CNKI, VIP, Wanfang, and CBM. Reviewers independently conducted study selection, data extraction, and bias risk using the Cochrane RoB 2.0. The principal endpoints included total effective rate and pulmonary function parameters; secondary endpoints comprised arterial blood gas indices, inflammatory markers, and adverse events. A frequentist-based analytical strategy was utilized, with StataSE 18.0 for analysis.
Results:
84 RCTs comprising 8,477 participants and 10 CPMs were included. ZCL showed the greatest improvement in total effective rate (RR 4.26, 95% CI 2.24-8.09; SUCRA 72.4%). SWLDH ranked highest for FVC (MD 0.58, 95% CI 0.29-0.87; SUCRA 94.5%) and FEV1 (MD 0.85, 95% CI 0.56-1.15; SUCRA 98.0%). QKL demonstrated the most significant effect on FEV1/FVC (MD 8.57, 95% CI 3.80-13.34; SUCRA 87.0%) and also ranked first for pH. XZL was superior in PaO2 and IL-6, while RDN best reduced PaCO2 and IL-8. QQHT was most effective for TNF-α. The analysis found no statistically significant increase in the risk of adverse events for any CPM + CT, compared to CT alone. The level of evidence certainty was categorized as low or very low.
Conclusion:
CPMs may improve total effective rate, pulmonary function, blood gas parameters, and inflammatory markers in AECOPD. However, these findings require confirmation by high-quality studies.
Systematic Review Registration:
[https://www.crd.york.ac.uk/PROSPERO/view/], identifier [CRD420251059887].
More Related Videos
Related Concept Videos
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

